Yttrium-90 and Rhenium-188 Radiopharmaceuticals for Radionuclide Therapy

complex thus prepared shows bone affinity in mice, with bone uptake occurring
more slowly but reaching a higher percentage of injected dose per gram weight
(%ID/g) than 99m Tc MDP by 150 min postinjection (p.i.); this continued to
increase beyond 350 min thereafter, with no significant soft tissue uptake. Again,
because of the well defined coordination chemistry, it is expected that the 188 Re
complex will behave similarly. The two classes of bisphosphonate derivative
have also shown outstanding affinity for binding to inorganic nanoparticulate
materials (HA and superparamagnetic iron oxides), with potential applications in
multimodality imaging and radionuclide therapy.
Preliminary results on the labelling and quality control of the classical
bisphosphonate ligands (1-hydroxyethan-1,1-diyl)bis(phosphonic acid) (HEDP)
(Serbia), MDP, ethylenediametetrametylenephosphoric acid (EDTMP) and
clodronate (Brazil) with both 186 Re and 188 Re have been reported.
1.3.10. Rhenium-188(V) DMSA
The groups in Poland and Serbia investigated the production of the
therapeutic agent 188 Re(V) dimercaptosuccinic acid (DMSA) previously
proposed for the treatment of medullary carcinoma. The preparation route was
devised through a modification of the existing kit formulation currently used for
preparing the corresponding 99m Tc analogue 99m Tc(V) DMSA. Using this agent,
the group in Serbia started a clinical trial involving a limited number of patients
and presented the first results of this study.
Similarly, the group in Brazil conducted a few experiments on the labelling
of DMSA with 188 Re using two alternative routes: (i) through a commercial kit
formulation used for the preparation of the corresponding 99m Tc analogue and
(ii) through the oxalate method employed for the efficient reduction of the
starting tetraoxo 188 Re anion.
8